Related Experiment Videos
Glucose-6-phosphate dehydrogenase deficiency: a potential source of severe neonatal hyperbilirubinaemia and
Michael Kaplan1, Cathy Hammerman
1Department of Neonatology, Shaare Zedek Medical Center, and the Faculty of Medicine of the Hebrew University, Jerusalem, Israel. kaplan@cc.huji.ac.il
Insights
Glucose-6-phosphate dehydrogenase (G-6-PD) deficiency can cause severe jaundice in newborns. Early screening and awareness are crucial for managing this common enzyme defect and preventing serious complications like kernicterus.
Area of Science:
- Medical Genetics
- Neonatology
- Biochemistry
Background:
- Glucose-6-phosphate dehydrogenase (G-6-PD) deficiency is a prevalent enzyme defect.
- It is a significant cause of severe neonatal hyperbilirubinemia and kernicterus.
- Pathogenesis involves increased hemolysis and diminished bilirubin conjugation, exacerbated by factors like Gilbert's syndrome.
Purpose of the Study:
- To highlight the clinical significance of G-6-PD deficiency in neonates.
- To discuss the contributing factors to hyperbilirubinemia in affected infants.
- To review current and potential treatment strategies.
Main Methods:
- Literature review of G-6-PD deficiency, neonatal jaundice, and treatment modalities.
- Analysis of contributing factors to hyperbilirubinemia in G-6-PD deficient neonates.
- Evaluation of diagnostic and therapeutic interventions.
Main Results:
- G-6-PD deficiency contributes to neonatal jaundice through hemolysis and impaired bilirubin conjugation.
- Phototherapy is the primary treatment; exchange transfusion is reserved for severe cases.
- Sn-mesoporphyrins offer a pharmacological approach to reduce bilirubin levels.
- Predischarge bilirubin screening effectively identifies at-risk neonates.
Conclusions:
- G-6-PD deficiency is a global health concern due to migration patterns.
- Physician awareness and early screening are essential for timely diagnosis and management.
- Effective management strategies can prevent severe hyperbilirubinemia and kernicterus.
Abstract:
Glucose-6-phosphate dehydrogenase (G-6-PD) deficiency is a commonly occurring enzyme defect that can lead to severe neonatal hyperbilirubinaemia and kernicterus. Both increased haemolysis, sometimes due to an identifiable chemical trigger or to infection, and diminished bilirubin conjugation, the result of an interaction between G-6-PD deficiency and Gilbert's syndrome, contribute to the pathogenesis of the jaundice. Phototherapy is the mainstay of treatment, with exchange transfusion held in reserve for those neonates who do not respond to phototherapy. Pharmacological agents such as Sn-mesoporphyrins, which prevent bilirubin production by inhibiting the enzyme heme oxygenase, can limit hyperbilirubinaemia and possibly prevent the need for exchange transfusion. Predischarge serum total bilirubin screening is useful in predicting which neonates are at high risk for developing hyperbilirubinaemia. Migration patterns make G-6-PD deficiency a condition which may nowadays be encountered in virtually any corner of the globe and a high degree of physician awareness is essential.